Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

Status Completed

Clinical Trial Summary

Food allergy occurs when the immune system reacts against foods. The immune system is the part of the body that protects us from illness and germs, but it can also cause allergies. Peanut allergy occurs in 1 - 2% of people in the United States and other Western countries. There is proof that allergy to peanut is increasing. Allergic reactions to peanut can be severe and life threatening. The only way that you can prevent an allergic reaction is to avoid exposure to peanuts. However, peanut proteins are found in a variety of foods and people can be accidently exposed to peanut proteins. Treatment for accidental exposure include antihistamines (medications like Benadryl), and injectable epinephrine (adrenalin) which must be carried at all times. DBV Technologies has developed an epicutaneous delivery system, a patch that puts the peanut protein on the skin.

Clinical Trial Description

This study will evaluate whether peanut epicutaneous immunotherapy can protect individuals who are allergic to peanuts from having severe allergic reactions, when accidentally exposed to peanuts. The study also looks at the safety of the treatment and the effects it has on the immune system. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01904604
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 2
Start date	September 2013
Completion date	August 21, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04531540` - Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)	Phase 3
Completed	`NCT00988065` - Sugammadex Hypersensitivity Study (Study P06042)	Phase 1
Completed	`NCT03563066` - Effect of Benralizumab in Atopic Dermatitis	Phase 2
Completed	`NCT02588326` - Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays	Phase 1
Completed	`NCT02916888` - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists	N/A
Completed	`NCT02360072` - Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma
Completed	`NCT02352168` - Airway Inflammation in Children With Allergic Rhinitis and Intervention	N/A
Completed	`NCT01494649` - Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity	N/A
Enrolling by invitation	`NCT05039229` - Measures for Bioaerosol Reduction in the Salmon Industry	N/A
Enrolling by invitation	`NCT05675241` - Characterizing the Inflammation Around Dental Implants
Completed	`NCT04006106` - Defining ENDOtypes in Perioperative Hypersensitivity by Extensive Cellular and Molecular PHENotyping (ENDOPHEN)
Completed	`NCT04605471` - A Study to Learn More About the Safety of Ultravist in Children and in the Elderly
Completed	`NCT03720470` - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Phase 3
Terminated	`NCT05247567` - Quaternary Ammonium and Immunization in Hairdressers	N/A
Completed	`NCT05119751` - Vestibular Versus Sublingual Route of AIT Tablets	Phase 4
Recruiting	`NCT06065137` - Standardised Drug Provocation Testing in Perioperative Hypersensitivity	N/A
Active, not recruiting	`NCT05960266` - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study	Early Phase 1
Not yet recruiting	`NCT04485299` - Clinical Assessment of Bifluorid 10 vs Varnish Fluoride on The Exposed Hypersensitive Cervical Dentin in Adult Patient	Phase 2/Phase 3
Completed	`NCT02686827` - DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.	Phase 2
Completed	`NCT00850668` - Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults	Phase 1